臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52878601 線上人數 : 715 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"hsu c"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 331-340 / 881 (共89頁)
<< < 29 30 31 32 33 34 35 36 37 38 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-03-15T07:44:49Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:46Z	Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges	LI-CHUN LU; Hsu C.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:44Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:43Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T07:44:43Z	Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma	Li-Chun Lu;Hsu C.;Shao Y.-Y.;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L.; LI-CHUN LU; Hsu C.; Shao Y.-Y.; Chao Y.; Yen C.-J.; Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T06:27:34Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-03-15T06:27:33Z	The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines	Chen W.-W.; DWANG-YING CHANG; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L.
臺大學術典藏	2021-03-12T00:51:01Z	Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer	Chang Y.-T.;Chang M.-C.;Wei S.-C.;Tien Y.-W.;Hsu C.;Liang P.-C.;Tsao P.-N.;I-Shiow Jan;Wong J.-M.; Chang Y.-T.; Chang M.-C.; Wei S.-C.; Tien Y.-W.; Hsu C.; Liang P.-C.; Tsao P.-N.; I-SHIOW JAN; Wong J.-M.
臺大學術典藏	2021-03-09T06:46:18Z	MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer	Hsu C.;Yeh K.-H.;Ruey-Long Hong;Yang C.-H.;Lin M.-T.;Chen Y.-C.;Cheng A.-L.; Hsu C.; Yeh K.-H.; RUEY-LONG HONG; Yang C.-H.; Lin M.-T.; Chen Y.-C.; Cheng A.-L.
臺大學術典藏	2021-03-09T06:46:11Z	Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate	Lin C.-H.;Yen R.-F.;Jeng Y.-M.;Tzen C.-Y.;Hsu C.;Ruey-Long Hong; Lin C.-H.; Yen R.-F.; Jeng Y.-M.; Tzen C.-Y.; Hsu C.; RUEY-LONG HONG

顯示項目 331-340 / 881 (共89頁)
<< < 29 30 31 32 33 34 35 36 37 38 > >>
每頁顯示[10|25|50]項目